The once‐daily human GLP‐1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short‐term treatment
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.12108
Authors: A. Flint, C. Kapitza, M. Zdravkovic
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Novo Nordisk
OpenAlex ID: W1547965481
